We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Stroke Genetics Study Triples Number of Known Risk Loci

By LabMedica International staff writers
Posted on 11 Apr 2018
Results of one of the largest genome-wide-association studies (GWAS) to be carried out on stroke revealed 22 new stroke risk loci, bringing the total to 32, which more than triples the number of gene regions known to affect stroke risk.

The study was conducted under the auspices of MEGASTROKE, a project of the International Stroke Genetics Consortium, a multi-disciplinary collaborative of experts in stroke genetics. More...
MEGASTROKE members include research groups from the United States, Germany, France, the United Kingdom, Japan, Iceland, Spain, Switzerland, Italy, Belgium, the Netherlands, Denmark, Sweden, Norway, Finland, Estonia, Poland, Singapore, Australia, and Canada.

In the current study, 521,612 DNA samples (from 67,162 cases and 454,450 controls) provided by individuals from Europe, North and South America, Asia, Africa, and Australia were analyzed. In addition, data from 29 other large genetic studies were incorporated for analysis.

Results published in the March 12, 2018, online edition of the journal Nature Genetics revealed 22 new stroke risk loci. In addition, the investigators found shared genetic variation with related vascular traits, including blood pressure, cardiac traits, and venous thromboembolism at 18 individual loci. Eleven new susceptibility loci indicated mechanisms not previously implicated in stroke pathophysiology, and several of the implicated genes were considered to be potential new drug targets for stroke treatment and prevention.

"This study really advances what we know about the genetics of stroke," said contributing author Dr. Steven Kittner, professor of neurology at the University of Maryland School of Medicine (Baltimore, USA). "With this new information we can help researchers work to develop new treatments and new therapies."

"These findings, which link stroke with multiple other diseases, and with dysregulation of genes, proteins, and molecular pathways in specific cell types and organs, were generated using novel bioinformatics approaches that use information from many international biological databases. This work underscores the vital importance of data sharing," said contributing author Dr. Braxton Mitchell, professor of medicine at the University of Maryland School of Medicine.

Related Links:
International Stroke Genetics Consortium
University of Maryland School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Urine Analyzer
respons® UDS100
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.